Malignant Neoplasm of Stomach Completed Phase 2 Trials for Oxaliplatin (DB00526)

Also known as: Gastric Cancers / Stomach Cancer / Gastric cancer / Gastric Malignancies / Gastric cancer NOS / Cancer of Stomach / Malignant neoplasm of stomach, unspecified / Gastric malignancy

IndicationStatusPhase
DBCOND0045917 (Malignant Neoplasm of Stomach)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00525785Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)Treatment
NCT01246960A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal CancerTreatment
NCT01748773A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction CancerTreatment
NCT01913639FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric CancerTreatment
NCT01747551FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric CancerTreatment
NCT00601705Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or StomachTreatment
NCT00217581Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction CancerTreatment
NCT01364493A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric CancerTreatment
NCT00004127Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or StomachTreatment
NCT00040859Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach CancerTreatment
NCT00398398Study of XELOX With Cetuximab in Advanced Gastric CancerTreatment
NCT00436241A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.Treatment
NCT00447967Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric PatientsTreatment
NCT00454636A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.Treatment
NCT00514020Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction CancerTreatment
NCT00673673FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric CancerTreatment
NCT00737373Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus CancerTreatment
NCT00733616Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General StatusTreatment
NCT00816543Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal AdenocarcinomaTreatment
NCT00849615Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionTreatment
NCT01130337A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric CancerTreatment
NCT01130805A Study of Pazopanib With CAPEOX in AGC PatientsTreatment
NCT01138904FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)Treatment
NCT01379482Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric CancerTreatment
NCT01590719A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal CancerTreatment